<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02106767</url>
  </required_header>
  <id_info>
    <org_study_id>14-12970</org_study_id>
    <nct_id>NCT02106767</nct_id>
  </id_info>
  <brief_title>The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin</brief_title>
  <official_title>The Effects of Single-Dose Rifampin on the Pharmacokinetics of Rosuvastatin in Healthy White and Asian Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of transporter inhibition by rifampin on the pharmacokinetics of rosuvastatin will
      be studied in clinical trial in White and Asian healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area-under-the-concentration curve (AUC) of rosuvastatin</measure>
    <time_frame>Blood samples collected over a 48 hour period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 32, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to concentration maximum (Tmax) of rosuvastatin</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 24, 32, and 48 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampin plus rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Rosuvastatin 20mg po x1</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin plus rifampin</intervention_name>
    <description>Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1</description>
    <arm_group_label>Rifampin plus rosuvastatin</arm_group_label>
    <other_name>Crestor</other_name>
    <other_name>Rifadin</other_name>
    <other_name>Rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Asian volunteers of Han-Chinese/Japanese/Korean descent whose parents and
             grandparents are Han-Chinese/ Japanese/ Korean.

          -  Healthy Caucasian volunteers of White/Caucasian/European-born descent whose parents
             and grandparents are White/Caucasian/European.

          -  Male or female, ages 18-65 years old, with no current medical conditions or active
             diagnoses as determined by the study doctor based on history, physical exam, and
             laboratory evaluations.

          -  Subjects who take no other medications two weeks prior to the study and during the
             time course of the study including prescription medications, over-the-counter
             medications, dietary supplements, or drugs of abuse.

          -  Subjects with the following genotype: SLCO1B1*1a and ABCG2 421CC.

          -  Subjects able to maintain adequate birth control during the study independent of
             hormonal contraceptive use.

          -  Subjects able to abstain from grapefruit, grapefruit juice, oranges, orange juice,
             caffeinated beverages and/or alcoholic beverages from 7am the day before the study to
             completion of that study day.

          -  Participants determined to have normal liver and kidney function as measured at
             baseline

          -  BMI between 18.0 - 30 kg/m2

          -  Subjects capable of fasting from food and beverages at least 8 hours prior to
             medication dosing.

          -  Be able to read, speak, and understand English.

          -  Subjects capable of providing informed consent and completing the requirements of the
             study.

        Exclusion Criteria:

          -  Subjects with active medical problems

          -  Subjects on chronic prescription or OTC medication that cannot be stopped 2 weeks
             prior to and during the study.

          -  Subjects incapable of multiple blood draws (HCT &lt; 30mg/dL)

          -  Subjects with a history of rhabdomyolysis

          -  Subjects with a history of drug-related myalgias

          -  Subjects with a history or diagnosis of hemorrhagic tendencies or blood dyscrasias

          -  Subjects with a history of GI bleed or peptic ulcer disease

          -  Subjects who smoke tobacco or have ongoing alcohol or illegal drug use

          -  Subjects who are pregnant, lactating, or trying to conceive during the study period

          -  Subjects allergic to rosuvastatin or rifampin or any known component of the
             medications

          -  Anyone who in the opinion of the study investigators is unable to do the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leslie Z Benet, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynda Frassetto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTSI Clinical Research Center, UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 3, 2014</study_first_submitted>
  <study_first_submitted_qc>April 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2014</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rosuvastatin</keyword>
  <keyword>rifampin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug interaction</keyword>
  <keyword>healthy volunteer</keyword>
  <keyword>drug transporter</keyword>
  <keyword>Asian</keyword>
  <keyword>White</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

